Shots: The P-III EXPAND study involves assessing of Mayzent vs PBO in 1,651 patients with SPMS from 31 countries with varying levels of disability (Core Part), EDSS scores of 3·0–6·5, followed by extended treatment with open-label BAF312 to evaluate long-term safety, tolerability and efficacy The P-III EXPAND study: 52% reduction in ARR in Mayzent group; […]Read More
Tags : EXPAND Study
Latest Posts
Categories
Related Topics
AbbVie
Acquire
Adults
Agreement
Amgen
approval
AstraZeneca
Bayer
Biosimilar
BMS
Collaborate
Collaborates
Collaboration
Commercialize
COVID-19
Develop
Development
Eli Lilly
Exclusive
FDA
Gilead
GSK
Janssen
Launches
License
License Agreement
Merck
Novartis
P-III
patients
Pfizer
receives
Regeneron
Report
reports
results
Roche
Sanofi
Signs
study
Takeda
the US FDA
Treat
Treatment
US